TISIDB

Summary
Symbol	BCL2L1
Name	BCL2-like 1
Aliases	BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location	20q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Isoform Bcl-X(L): Mitochondrion inner membrane Mitochondrion outer membrane Mitochondrion matrix Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane Cytoplasm, cytosol Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Nucleus membrane Single-pass membrane protein Cytoplasmic side Note=After neuronal stimulation, translocates from cytosol to synaptic vesicle and mitochondrion membrane in a calmodulin-dependent manner (By similarity). Localizes to the centrosome when phosphorylated at Ser-49.
Domain	PF00452 Apoptosis regulator proteins PF02180 Bcl-2 homology region 4
Function	Potent inhibitor of cell death. Inhibits activation of caspases. Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.; FUNCTION: Isoform Bcl-X(L) also regulates presynaptic plasticity, including neurotransmitter release and recovery, number of axonal mitochondria as well as size and number of synaptic vesicle clusters. During synaptic stimulation, increases ATP availability from mitochondria through regulation of mitochondrial membrane ATP synthase F(1)F(0) activity and regulates endocytic vesicle retrieval in hippocampal neurons through association with DMN1L and stimulation of its GTPase activity in synaptic vesicles. May attenuate inflammation impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed:17418785). ; FUNCTION: Isoform Bcl-X(S) promotes apoptosis.

> Gene Ontology [ TOP ]
Biological Process	GO:0000075 cell cycle checkpoint GO:0000910 cytokinesis GO:0001101 response to acid chemical GO:0001541 ovarian follicle development GO:0001701 in utero embryonic development GO:0001836 release of cytochrome c from mitochondria GO:0006839 mitochondrial transport GO:0007006 mitochondrial membrane organization GO:0007009 plasma membrane organization GO:0007093 mitotic cell cycle checkpoint GO:0007281 germ cell development GO:0007283 spermatogenesis GO:0007346 regulation of mitotic cell cycle GO:0007548 sex differentiation GO:0008406 gonad development GO:0008584 male gonad development GO:0008585 female gonad development GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008637 apoptotic mitochondrial changes GO:0009314 response to radiation GO:0009566 fertilization GO:0009615 response to virus GO:0010212 response to ionizing radiation GO:0010332 response to gamma radiation GO:0010639 negative regulation of organelle organization GO:0010821 regulation of mitochondrion organization GO:0010823 negative regulation of mitochondrion organization GO:0019048 modulation by virus of host morphology or physiology GO:0019050 suppression by virus of host apoptotic process GO:0019054 modulation by virus of host process GO:0022412 cellular process involved in reproduction in multicellular organism GO:0022602 ovulation cycle process GO:0033668 negative regulation by symbiont of host apoptotic process GO:0035821 modification of morphology or physiology of other organism GO:0038034 signal transduction in absence of ligand GO:0039526 modulation by virus of host apoptotic process GO:0042391 regulation of membrane potential GO:0042698 ovulation cycle GO:0043200 response to amino acid GO:0043279 response to alkaloid GO:0043523 regulation of neuron apoptotic process GO:0043524 negative regulation of neuron apoptotic process GO:0044003 modification by symbiont of host morphology or physiology GO:0044068 modulation by symbiont of host cellular process GO:0044531 modulation of programmed cell death in other organism GO:0044532 modulation of apoptotic process in other organism GO:0045137 development of primary sexual characteristics GO:0045786 negative regulation of cell cycle GO:0045930 negative regulation of mitotic cell cycle GO:0046545 development of primary female sexual characteristics GO:0046546 development of primary male sexual characteristics GO:0046660 female sex differentiation GO:0046661 male sex differentiation GO:0046898 response to cycloheximide GO:0046902 regulation of mitochondrial membrane permeability GO:0048232 male gamete generation GO:0048511 rhythmic process GO:0048608 reproductive structure development GO:0051402 neuron apoptotic process GO:0051701 interaction with host GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction GO:0051881 regulation of mitochondrial membrane potential GO:0052040 modulation by symbiont of host programmed cell death GO:0052041 negative regulation by symbiont of host programmed cell death GO:0052150 modulation by symbiont of host apoptotic process GO:0052248 modulation of programmed cell death in other organism involved in symbiotic interaction GO:0052433 modulation by organism of apoptotic process in other organism involved in symbiotic interaction GO:0052490 negative regulation by organism of programmed cell death in other organism involved in symbiotic interaction GO:0060154 cellular process regulating host cell cycle in response to virus GO:0061458 reproductive system development GO:0070584 mitochondrion morphogenesis GO:0070997 neuron death GO:0071214 cellular response to abiotic stimulus GO:0071229 cellular response to acid chemical GO:0071230 cellular response to amino acid stimulus GO:0071312 cellular response to alkaloid GO:0071417 cellular response to organonitrogen compound GO:0071478 cellular response to radiation GO:0071479 cellular response to ionizing radiation GO:0071480 cellular response to gamma radiation GO:0071839 apoptotic process in bone marrow GO:0072657 protein localization to membrane GO:0072659 protein localization to plasma membrane GO:0090002 establishment of protein localization to plasma membrane GO:0090003 regulation of establishment of protein localization to plasma membrane GO:0090005 negative regulation of establishment of protein localization to plasma membrane GO:0090150 establishment of protein localization to membrane GO:0090199 regulation of release of cytochrome c from mitochondria GO:0090201 negative regulation of release of cytochrome c from mitochondria GO:0090559 regulation of membrane permeability GO:0097191 extrinsic apoptotic signaling pathway GO:0097192 extrinsic apoptotic signaling pathway in absence of ligand GO:0097193 intrinsic apoptotic signaling pathway GO:0097194 execution phase of apoptosis GO:0097284 hepatocyte apoptotic process GO:0097305 response to alcohol GO:0098586 cellular response to virus GO:1900117 regulation of execution phase of apoptosis GO:1900118 negative regulation of execution phase of apoptosis GO:1901099 negative regulation of signal transduction in absence of ligand GO:1901214 regulation of neuron death GO:1901215 negative regulation of neuron death GO:1901654 response to ketone GO:1902229 regulation of intrinsic apoptotic signaling pathway in response to DNA damage GO:1902230 negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage GO:1902532 negative regulation of intracellular signal transduction GO:1903076 regulation of protein localization to plasma membrane GO:1903077 negative regulation of protein localization to plasma membrane GO:1903729 regulation of plasma membrane organization GO:1903828 negative regulation of cellular protein localization GO:1904019 epithelial cell apoptotic process GO:1904375 regulation of protein localization to cell periphery GO:1904376 negative regulation of protein localization to cell periphery GO:1904950 negative regulation of establishment of protein localization GO:1990778 protein localization to cell periphery GO:2001020 regulation of response to DNA damage stimulus GO:2001021 negative regulation of response to DNA damage stimulus GO:2001233 regulation of apoptotic signaling pathway GO:2001234 negative regulation of apoptotic signaling pathway GO:2001235 positive regulation of apoptotic signaling pathway GO:2001236 regulation of extrinsic apoptotic signaling pathway GO:2001237 negative regulation of extrinsic apoptotic signaling pathway GO:2001239 regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001242 regulation of intrinsic apoptotic signaling pathway GO:2001243 negative regulation of intrinsic apoptotic signaling pathway GO:2001244 positive regulation of intrinsic apoptotic signaling pathway
Molecular Function	GO:0046982 protein heterodimerization activity GO:0051400 BH domain binding GO:0051434 BH3 domain binding GO:0070513 death domain binding
Cellular Component	GO:0005635 nuclear envelope GO:0005741 mitochondrial outer membrane GO:0005743 mitochondrial inner membrane GO:0005759 mitochondrial matrix GO:0005813 centrosome GO:0008021 synaptic vesicle GO:0019867 outer membrane GO:0030133 transport vesicle GO:0030658 transport vesicle membrane GO:0030659 cytoplasmic vesicle membrane GO:0030672 synaptic vesicle membrane GO:0031965 nuclear membrane GO:0031968 organelle outer membrane GO:0070382 exocytic vesicle GO:0097136 Bcl-2 family protein complex GO:0098793 presynapse GO:0099501 exocytic vesicle membrane GO:0099503 secretory vesicle

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04014 Ras signaling pathway hsa04064 NF-kappa B signaling pathway hsa04140 Regulation of autophagy hsa04151 PI3K-Akt signaling pathway hsa04210 Apoptosis hsa04621 NOD-like receptor signaling pathway hsa04630 Jak-STAT signaling pathway
Reactome	R-HSA-109581: Apoptosis R-HSA-111453: BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-168256: Immune System R-HSA-622312: Inflammasomes R-HSA-168249: Innate Immune System R-HSA-6785807: Interleukin-4 and 13 signaling R-HSA-109606: Intrinsic Pathway for Apoptosis R-HSA-168643: Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways R-HSA-5357801: Programmed Cell Death R-HSA-449147: Signaling by Interleukins R-HSA-844455: The NLRP1 inflammasome

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04014 Ras signaling pathway
hsa04064 NF-kappa B signaling pathway
hsa04140 Regulation of autophagy
hsa04151 PI3K-Akt signaling pathway
hsa04210 Apoptosis
hsa04621 NOD-like receptor signaling pathway
hsa04630 Jak-STAT signaling pathway

Reactome

R-HSA-109581: Apoptosis
R-HSA-111453: BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-622312: Inflammasomes
R-HSA-168249: Innate Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-109606: Intrinsic Pathway for Apoptosis
R-HSA-168643: Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
R-HSA-5357801: Programmed Cell Death
R-HSA-449147: Signaling by Interleukins
R-HSA-844455: The NLRP1 inflammasome

Summary
Symbol	BCL2L1
Name	BCL2-like 1
Aliases	BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location	20q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between BCL2L1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between BCL2L1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
10697273	Central nervous system lymphoma	Inhibit immunity	Overexpression of BCL-2, BCL-X, and BAX in primary central nervous system lymphomas that occur in immunosuppressed patients.
19454669	Lymphoma	Promote immunity (T cell function)	In vivo, with response to tumor-expressed Ag following adoptive T cell transfer, Ag-reactive CD8(+) T cells expressing both Bcl-x(L) and survivin displayed greatly enhanced tumor protective activity compared with CD8(+) T cells expressing either molecule introduced separately. These results indicate that Bcl-x(L) and survivin can critically contribute in a cooperative, nonredundant manner to augment the accumulation and persistence of CD8(+) T cells following encounter with Ag.
16148096	Thymoma	Promote immunity	OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen. The lack of OX40 costimulation was associated with reduced levels of Bcl-x(L), and retroviral expression of Bcl-x(L) in tumor-reactive CD8 T cells conferred greatly enhanced tumor protection following adoptive transfer.
25070854	lymphoma	Promote immunity	We found that overexpression or induction of Bcl-xL led to increased Ag presentation to NKT cells. Conversely, the inhibition or knockdown of Bcl-xL led to decreased NKT cell activation.

Summary
Symbol	BCL2L1
Name	BCL2-like 1
Aliases	BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location	20q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of BCL2L1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	BCL2L1
Name	BCL2-like 1
Aliases	BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location	20q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of BCL2L1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.15	0.514
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.66	0.803
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.219	0.908
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.645	0.0448
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.754	0.705
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.509	0.843
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.234	0.591
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.163	0.926
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.698	0.722
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.029	0.989
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.047	0.988
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.02	0.798

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of BCL2L1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	BCL2L1
Name	BCL2-like 1
Aliases	BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location	20q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BCL2L1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	BCL2L1
Name	BCL2-like 1
Aliases	BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location	20q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BCL2L1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BCL2L1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	BCL2L1
Name	BCL2-like 1
Aliases	BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location	20q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BCL2L1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	BCL2L1
Name	BCL2-like 1
Aliases	BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location	20q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of BCL2L1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	BCL2L1
Name	BCL2-like 1
Aliases	BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location	20q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between BCL2L1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	BCL2L1
Name	BCL2-like 1
Aliases	BCLX; BCL2L; Bcl-X; bcl-xL; bcl-xS; PPP1R52; protein phosphatase 1, regulatory subunit 52; BCL-XL/S; BCLXL; ......
Chromosomal Location	20q11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting BCL2L1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting BCL2L1.

ID	Name	Drug Type	Targets	#Targets
DB07108	4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID	Small Molecule	BCL2L1	1
DB09401	Isosorbide	Small Molecule	BCL2, BCL2L1, MCL1	3
DB13044	Gossypol	Small Molecule	BCL2L1	1

Browse BCL2L1